Hormonal
GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) produce significant weight loss (6.2–15.8 kg) in adults with obesity, with efficacy increasing with higher doses.
GLP-1 agonists like semaglutide and liraglutide are effective for significant weight loss in adults with obesity, often outperforming lifestyle changes alone. Expect weight loss between 6-16 kg over several months. Be aware of gastrointestinal side effects, which are common but often manageable. These are prescription medications requiring medical supervision to manage dosing and side effects.
The results of such studies indicate that treatment with semaglutide, liraglutide and tirzepatide is particularly effective in terms of weight loss, with a loss of 6.2 kg to 15.8 kg over 16 to 68 weeks of treatment.
Why this rating
Systematic review of RCTs, but notes heterogeneity and lack of long-term real-world data.
Source
GLP-1 receptor agonists for weight loss, benefits and risks: A systematic review of the literature
Diego Silva Pacheco de Moraes et al. · Salud Ciencia y Tecnología - Serie de Conferencias · 2024
DOI 10.56294/sctconf2024.719
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →